title: Novel and selective calcitonin-inducing agents.
abstract: A series of xanthine sulfonamides is presented as a class of calcitonin (CT) inducers - a potentially new method for treating diseases associated with postmenopausal bone loss such as osteoporosis. We have found that certain di-n-butylxanthine sulfonamides 4 upregulate CT transcription in a CT-luciferase reporter gene assay (CT-luci) and increase the production and release of CT in a CT secretion/RIA assay (CTS). In addition, these compounds do not have potent PDE4 inhibitory activity as do the related xanthine methylene ketones such as denbufyllene (2). One compound in particular (9) shows a transcription activation ratio (TAR) of 2.1 in CT-luci, a CTS increase of 3.6-fold, and a PDE4 (phosphodiesterase type IV) IC(50) = 4.1 microM. In addition, this compound showed a statistically significant 47% trabecular bone protection in ovariectomized-induced osteopenia (OVX) rats as determined by assay when administered for 4 weeks at 30 mg/kg/day, i. p. by quantitative computed tomography (QCT). When administered p.o., compound 9 shows 50% trabecular bone protection when administered for 3 weeks at 50 mg/kg/day, i.p. This compared with salmon CT which shows 62% trabecular bone protection when administered at 50 IU/kg/day for 4 weeks.
authors.affiliation: Chemical Sciences, Wyeth-Ayerst Research, 401 North Middletown Road, Pearl River, New York 10965-1299, USA. gilbera@war.wyeth.com
authors.forename: A M
authors.initials: AM
authors.lastname: Gilbert
authors.forename: S
authors.initials: S
authors.lastname: Caltabiano
authors.forename: D
authors.initials: D
authors.lastname: Roberts
authors.forename: S F
authors.initials: SF
authors.lastname: Sum
authors.forename: G D
authors.initials: GD
authors.lastname: Francisco
authors.forename: K
authors.initials: K
authors.lastname: Lim
authors.forename: M
authors.initials: M
authors.lastname: Asselin
authors.forename: J W
authors.initials: JW
authors.lastname: Ellingboe
authors.forename: Y
authors.initials: Y
authors.lastname: Kharode
authors.forename: A
authors.initials: A
authors.lastname: Cannistraci
authors.forename: R
authors.initials: R
authors.lastname: Francis
authors.forename: M
authors.initials: M
authors.lastname: TrailSmith
authors.forename: D
authors.initials: D
authors.lastname: Gralnick
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000473:pathology; D002116:Calcitonin / Q000096:biosynthesis* / Q000235:genetics; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D017930:Genes, Reporter; D006801:Humans; D008156:Luciferases / Q000235:genetics; D010052:Ovariectomy; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D014158:Transcription, Genetic; D014970:Xanthines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology
chemical_list: C406346:1,3-dibutyl-7-(3-chloropropane-1-sulfonyl)-3,7-dihydropurine-2,6-dione; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D014970:Xanthines; D002116:Calcitonin; D008156:Luciferases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4